Tags

Type your tag names separated by a space and hit enter

Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
Brain. 2011 Jan; 134(Pt 1):50-8.B

Abstract

In vivo and post-mortem studies have demonstrated that increased nigral iron content in patients with Parkinson's disease is a prominent pathophysiological feature. However, the mechanism and risk factors associated with nigral iron deposition in patients with Parkinson's disease have not been identified and represent a key challenge in understanding its pathogenesis and for its diagnosis. In this study, we assessed iron levels in patients with Parkinson's disease and in age- and gender-matched control subjects by measuring phase values using magnetic resonance based susceptibility-weighted phase imaging in a 3T magnetic resonance system. Phase values were measured from brain regions including bilateral substantia nigra, globus pallidus, putamen, caudate, thalamus, red nucleus and frontal white matter of 45 patients with Parkinson's disease with decreased or normal serum ceruloplasmin levels, together with age- and gender-matched control subjects. Correlative analyses between phase values, serum ceruloplasmin levels and disease severity showed that the nigral bilateral average phase values in patients with Parkinson's disease were significantly lower than in control subjects and correlated with disease severity according to the Hoehn and Yahr Scale. The Unified Parkinson's Disease Rating Scale motor scores from the clinically most affected side were significantly correlated with the phase values of the contralateral substantia nigra. Furthermore, nigral bilateral average phase values correlated highly with the level of serum ceruloplasmin. Specifically, in the subset of patients with Parkinson's disease exhibiting reduced levels of serum ceruloplasmin, we found lowered nigral bilateral average phase values, suggesting increased nigral iron content, while those patients with normal levels of serum ceruloplasmin exhibited no changes as compared with control subjects. These findings suggest that decreased levels of serum ceruloplasmin may specifically exacerbate nigral iron deposition in patients with Parkinson's disease. Combining susceptibility-weighted phase imaging with serum ceruloplasmin determination is likely to be useful for the diagnosis and assessment of a subset of patients with Parkinson's disease.

Authors+Show Affiliations

Department of Neurology, Zhongshan Hospital and Shanghai Medical College, Fudan University, Shanghai, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21109502

Citation

Jin, Lirong, et al. "Decreased Serum Ceruloplasmin Levels Characteristically Aggravate Nigral Iron Deposition in Parkinson's Disease." Brain : a Journal of Neurology, vol. 134, no. Pt 1, 2011, pp. 50-8.
Jin L, Wang J, Zhao L, et al. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain. 2011;134(Pt 1):50-8.
Jin, L., Wang, J., Zhao, L., Jin, H., Fei, G., Zhang, Y., Zeng, M., & Zhong, C. (2011). Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain : a Journal of Neurology, 134(Pt 1), 50-8. https://doi.org/10.1093/brain/awq319
Jin L, et al. Decreased Serum Ceruloplasmin Levels Characteristically Aggravate Nigral Iron Deposition in Parkinson's Disease. Brain. 2011;134(Pt 1):50-8. PubMed PMID: 21109502.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. AU - Jin,Lirong, AU - Wang,Jian, AU - Zhao,Lei, AU - Jin,Hang, AU - Fei,Guoqiang, AU - Zhang,Yuwen, AU - Zeng,Mengsu, AU - Zhong,Chunjiu, Y1 - 2010/11/24/ PY - 2010/11/27/entrez PY - 2010/11/27/pubmed PY - 2011/1/22/medline SP - 50 EP - 8 JF - Brain : a journal of neurology JO - Brain VL - 134 IS - Pt 1 N2 - In vivo and post-mortem studies have demonstrated that increased nigral iron content in patients with Parkinson's disease is a prominent pathophysiological feature. However, the mechanism and risk factors associated with nigral iron deposition in patients with Parkinson's disease have not been identified and represent a key challenge in understanding its pathogenesis and for its diagnosis. In this study, we assessed iron levels in patients with Parkinson's disease and in age- and gender-matched control subjects by measuring phase values using magnetic resonance based susceptibility-weighted phase imaging in a 3T magnetic resonance system. Phase values were measured from brain regions including bilateral substantia nigra, globus pallidus, putamen, caudate, thalamus, red nucleus and frontal white matter of 45 patients with Parkinson's disease with decreased or normal serum ceruloplasmin levels, together with age- and gender-matched control subjects. Correlative analyses between phase values, serum ceruloplasmin levels and disease severity showed that the nigral bilateral average phase values in patients with Parkinson's disease were significantly lower than in control subjects and correlated with disease severity according to the Hoehn and Yahr Scale. The Unified Parkinson's Disease Rating Scale motor scores from the clinically most affected side were significantly correlated with the phase values of the contralateral substantia nigra. Furthermore, nigral bilateral average phase values correlated highly with the level of serum ceruloplasmin. Specifically, in the subset of patients with Parkinson's disease exhibiting reduced levels of serum ceruloplasmin, we found lowered nigral bilateral average phase values, suggesting increased nigral iron content, while those patients with normal levels of serum ceruloplasmin exhibited no changes as compared with control subjects. These findings suggest that decreased levels of serum ceruloplasmin may specifically exacerbate nigral iron deposition in patients with Parkinson's disease. Combining susceptibility-weighted phase imaging with serum ceruloplasmin determination is likely to be useful for the diagnosis and assessment of a subset of patients with Parkinson's disease. SN - 1460-2156 UR - https://www.unboundmedicine.com/medline/citation/21109502/Decreased_serum_ceruloplasmin_levels_characteristically_aggravate_nigral_iron_deposition_in_Parkinson's_disease_ L2 - https://academic.oup.com/brain/article-lookup/doi/10.1093/brain/awq319 DB - PRIME DP - Unbound Medicine ER -